Journal of Health Economics and Outcomes Research, published by COLUMBIA DATA ANALYTICS, LLC, serves as a vital resource in the field of health policy and public health, providing researchers, professionals, and students with open access to pioneering studies since its inception in 2013. With its ISSN and E-ISSN both listed as 2327-2236, this journal aims to disseminate high-quality research that evaluates healthcare efficiency and outcomes. Situated in the United States, at 145 Hudson St., Suite 205, New York, NJ 10013, it has made significant strides in its category quartiles within the 2023 rankings, achieving Q2 status in both Health Policy and Public Health, Environmental and Occupational Health. Furthermore, it maintains respectable Scopus rankings, with a percentile of 51st in health policy and 49th in public health. By bridging gaps in health economics and policy discourse, the journal stands as an indispensable platform for advancing knowledge and fostering innovation in health services research.

Economics & Human Biology, published by Elsevier, is a prestigious journal that serves as an interdisciplinary platform at the intersection of economics and health sciences. With ISSN 1570-677X and E-ISSN 1873-6130, this journal analyzes the implications of economic factors on human health and biological outcomes. As a recognized leader in its field, it has earned a remarkable Q1 ranking in both the Economics, Econometrics and Finance (miscellaneous) and Health (social science) categories for 2023, reflecting its significant impact within the academic community, as evidenced by its Scopus rank of 88 out of 371 and a 76th percentile ranking in Health social sciences. Highlighting key issues such as health disparities, economic policy impacts on health, and the biological determinants of economic behavior, the journal encourages innovative research that bridges these critical domains. Researchers, professionals, and students seeking to contribute to or stay informed on emerging trends in health economics will find this journal an invaluable resource. Explore the latest findings and engage with a community dedicated to advancing our understanding of the interplay between economics and human biology.

ClinicoEconomics and Outcomes Research is a prestigious open-access journal published by DOVE MEDICAL PRESS LTD, located in New Zealand. Since its inception in 2009, it has established itself as a vital resource for researchers and practitioners in the fields of economics, health policy, and outcomes research. With a commendable impact reflected in its rankings—Q1 in Economics, Econometrics and Finance and Q2 in Health Policy—the journal effectively bridges the gap between economic evaluation and healthcare delivery. This publication is particularly significant for those focused on the economic implications of health interventions, policy analysis, and decision-making processes in healthcare systems. As an open-access journal, ClinicoEconomics and Outcomes Research ensures that its valuable content is widely accessible, enhancing knowledge dissemination and fostering collaboration among academia, industry, and policymakers. With an ambition to contribute to the improvement of health outcomes through rigorous research, it invites submissions that address the multifaceted challenges facing the economics of healthcare today. Join the scholarly dialogue where innovative ideas in health economics thrive!

Cost Effectiveness and Resource Allocation is a premier open-access journal published by BMC, dedicated to advancing the field of health policy and economics. Since its inception in 2003, the journal has provided a platform for researchers, policymakers, and healthcare professionals to disseminate crucial findings and insights relevant to cost-effectiveness analyses and resource allocation strategies. With an increasing impact factor and ranking within the Q2 category of health policy journals, it ranks #138 out of 310 in Scopus, placing it in the 55th percentile among its peers. The journal aims to facilitate knowledge exchange that can transform health policy and improve healthcare delivery through rigorous research, evaluation, and dialogue. Open access since its establishment, it ensures that critical findings are available to a global audience, thereby enhancing the impact and reach of its published works.

International Journal of Health Economics and Management is a premier academic journal published by SPRINGER, focusing on innovative research at the intersection of health economics and management practices. Established in 2015, this journal caters to a diverse range of disciplines, integrating rigorous economic analysis with vital health policy discussions. With an impressive impact factor reflective of its influential publications, it holds a distinguished Q1 ranking in Economics, Econometrics, and Finance, and a Q2 ranking in Health Policy for 2023. The journal provides an open access model, enabling wider dissemination of research findings to academics, policymakers, and healthcare professionals globally. Researchers and students alike will find this journal invaluable for its commitment to advancing knowledge in health economics and improving healthcare management practices through empirical studies and theoretical insights. For more information, or to access articles, please refer to the journal's platform.

Pharmacoeconomics-Open, an esteemed journal published by SPRINGER INT PUBL AG, is a vital resource for scholars and practitioners in the fields of health policy and pharmacology. Since its transition to an Open Access platform in 2017, the journal has aimed to democratize access to valuable research, fostering innovation and collaboration globally. With notable rankings in the 2023 Scopus indices—including Q2 in Health Policy and both categories of Pharmacology—Pharmacoeconomics-Open engages with pressing issues in health economics, providing insights into cost-effectiveness analyses and healthcare decision-making. The journal’s commitment to high-quality, peer-reviewed articles ensures that it remains a significant player in advancing knowledge and understanding within its disciplines, serving as an essential forum for researchers, policymakers, and students alike.

Health Policy OPEN is an esteemed open-access journal published by Elsevier that has made significant contributions to the field of health policy since its inception in 2020. With an impact factor placing it in the prestigious Q2 category of health policy journals, it ranks 116 out of 310 within the Scopus database, highlighting its critical engagement in the field and situating it within the 62nd percentile. As an open-access platform, Health Policy OPEN promotes the dissemination of high-quality research, making it accessible to a global audience of researchers, professionals, and students alike. The journal focuses on topical issues, innovative approaches, and evidence-based practices that shape health policies worldwide. With its headquarters in Amsterdam, Netherlands, the journal serves as a vital resource for advancing knowledge and fostering discussions that drive health policy initiatives and reforms. Engage with Health Policy OPEN to contribute to the evolving landscape of health policy and to stay informed on the latest research advancements.

Applied Economics, published by Routledge Journals, Taylor & Francis Ltd, is a revered platform in the field of Economics and Econometrics. Since its inception in 1969, the journal has maintained its commitment to disseminating high-quality research, covering a wide range of topics within applied economics that are critical for understanding and addressing real-world economic issues. With a notable Q2 ranking in Economics and Econometrics and a strong standing in the 67th percentile of Scopus rankings, it serves as an essential resource for researchers, professionals, and students alike, providing insights that bridge theoretical frameworks and practical applications. While the journal is not an Open Access platform, it continues to foster academic discourse and innovation within the economics community, contributing to the ongoing development of evidence-based policies and practices. Its accessibility and robust editorial standards ensure that the latest findings and methodologies reach an engaged audience, further solidifying its reputation as a key publication in the field.

PHARMACOECONOMICS, published by ADIS INT LTD, is a prestigious international journal dedicated to disseminating research in the fields of health policy, pharmacology, and public health. With an impressive impact factor and a solid Q1 ranking across its relevant categories, this journal plays a crucial role in shaping policy decisions, optimizing health resources, and enhancing pharmacoeconomic evaluations globally. The journal not only targets researchers and professionals but also serves as an invaluable resource for students striving to understand the economic implications of pharmaceutical care. Operating since 1992 and continuously evolving through 2024, PHARMACOECONOMICS invites contributions that address the complexities of drug expenditure, health outcomes, and public health implications, thereby fostering informed decision-making in healthcare systems. Readers can explore cutting-edge studies and analyses aimed at balancing cost-effectiveness with clinical effectiveness, making this journal a cornerstone for stakeholders invested in the future of health economics.

Expert Review of Pharmacoeconomics & Outcomes Research is a leading journal published by TAYLOR & FRANCIS LTD, focusing on the critical intersection of pharmacoeconomics and healthcare outcomes. Established in 2001, the journal has been a key resource for researchers and professionals in the fields of health policy, medicine, and pharmacology, consistently ranked in the top quartile of these categories for its influential insights. With an ISSN of 1473-7167 and an E-ISSN of 1744-8379, it delivers cutting-edge research that informs healthcare decisions and policy frameworks. The journal's rigorous peer-review process ensures the publication of high-quality, impactful articles that address contemporary challenges and advancements in pharmacoeconomic evaluations. As of 2023, it boasts a commendable ranking of #106 in Health Policy and #124 in Pharmacology, affirming its relevance and contribution to the field. Despite being a subscription-based journal, the strength of its content makes it an invaluable tool for researchers and practitioners aiming to enhance patient outcomes and optimize resource allocation in healthcare systems.